Review



boc  (Chem Impex International)


Bioz Verified Symbol Chem Impex International is a verified supplier
Bioz Manufacturer Symbol Chem Impex International manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Chem Impex International boc
    Boc, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/boc/product/Chem Impex International
    Average 96 stars, based on 1 article reviews
    boc - by Bioz Stars, 2026-02
    96/100 stars

    Images



    Similar Products

    boc  (Chem Impex International)
    96
    Chem Impex International boc
    Boc, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/boc/product/Chem Impex International
    Average 96 stars, based on 1 article reviews
    boc - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    mouse anti­human fgf23 monoclonal antibody  (Novus Biologicals)
    94
    Novus Biologicals mouse anti­human fgf23 monoclonal antibody
    (A) IHC indicated the expression levels of <t>FGF23</t> in the UNSM, ULM, and US groups. (B) The box plot shows FGF23 expression in US, ULM, and UNSM among six paired samples. (C) The box plot shows FGF23 expression in US and UNSM among 32 paired samples. US, uterine sarcoma; IHC, immunohistochemistry; UNSM, uterine normal smooth muscle; ULM, uterine leiomyoma.
    Mouse Anti­Human Fgf23 Monoclonal Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti­human fgf23 monoclonal antibody/product/Novus Biologicals
    Average 94 stars, based on 1 article reviews
    mouse anti­human fgf23 monoclonal antibody - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    sesn2 whole body ko mice  (Cyagen Biosciences)
    93
    Cyagen Biosciences sesn2 whole body ko mice
    <t>Sesn2</t> knockout aggravates obesity in female mice. ( A - B ) mice in four groups; ( C ) body weight; ( D - E ) fat mass; ( F ) FFA; ( G ) TG; ( H ) FBG; ( I - J ) OGTT and ITT; n = 4–6/group. * P < 0.05; # P < 0.05 vs. KO-NC. + P < 0.05 vs. WT-HFD
    Sesn2 Whole Body Ko Mice, supplied by Cyagen Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sesn2 whole body ko mice/product/Cyagen Biosciences
    Average 93 stars, based on 1 article reviews
    sesn2 whole body ko mice - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    mouse anti human fgf23 monoclonal antibody nbp3-07378  (Novus Biologicals)
    90
    Novus Biologicals mouse anti human fgf23 monoclonal antibody nbp3-07378
    <t>Sesn2</t> knockout aggravates obesity in female mice. ( A - B ) mice in four groups; ( C ) body weight; ( D - E ) fat mass; ( F ) FFA; ( G ) TG; ( H ) FBG; ( I - J ) OGTT and ITT; n = 4–6/group. * P < 0.05; # P < 0.05 vs. KO-NC. + P < 0.05 vs. WT-HFD
    Mouse Anti Human Fgf23 Monoclonal Antibody Nbp3 07378, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human fgf23 monoclonal antibody nbp3-07378/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    mouse anti human fgf23 monoclonal antibody nbp3-07378 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    mouse anti human fgf23 monoclonal antibody  (Novus Biologicals)
    94
    Novus Biologicals mouse anti human fgf23 monoclonal antibody
    (A) IHC indicated the expression levels of <t>FGF23</t> in the UNSM, ULM and US groups. (B) The box plot shows FGF23 expression in US, ULM, and UNSM among 6 paired samples. (C) The box plot shows FGF23 expression in US and UNSM among 32 paired samples.
    Mouse Anti Human Fgf23 Monoclonal Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human fgf23 monoclonal antibody/product/Novus Biologicals
    Average 94 stars, based on 1 article reviews
    mouse anti human fgf23 monoclonal antibody - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) IHC indicated the expression levels of FGF23 in the UNSM, ULM, and US groups. (B) The box plot shows FGF23 expression in US, ULM, and UNSM among six paired samples. (C) The box plot shows FGF23 expression in US and UNSM among 32 paired samples. US, uterine sarcoma; IHC, immunohistochemistry; UNSM, uterine normal smooth muscle; ULM, uterine leiomyoma.

    Journal: Technology in Cancer Research & Treatment

    Article Title: Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma

    doi: 10.1177/15330338241245924

    Figure Lengend Snippet: (A) IHC indicated the expression levels of FGF23 in the UNSM, ULM, and US groups. (B) The box plot shows FGF23 expression in US, ULM, and UNSM among six paired samples. (C) The box plot shows FGF23 expression in US and UNSM among 32 paired samples. US, uterine sarcoma; IHC, immunohistochemistry; UNSM, uterine normal smooth muscle; ULM, uterine leiomyoma.

    Article Snippet: Immunohistochemistry (IHC) was performed using a mouse anti­human FGF23 monoclonal antibody (NBP3-07378; Novus Biologicals, Colorado, USA).

    Techniques: Expressing, Immunohistochemistry

    (A) IHC assay indicated FGF23 expression in different uterine sarcoma subtypes. (B) The box plot and scatter plot shows the differential expression of FGF23 in AS, ESS, LMS, and UCS. FGF23 intensity: 1+ = weak, 2+ = moderate, 3+ = strong, FGF23 expression: 1+ = 1-25%, 2+ = 25-50%, 3+ = 50-75%, 4+ = ＞75%. IHC, immunohistochemistry; UCS, uterine carcinosarcoma; LMS, leiomyosarcoma; ESS, endometrial stromal sarcoma; AS, adenosarcoma.

    Journal: Technology in Cancer Research & Treatment

    Article Title: Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma

    doi: 10.1177/15330338241245924

    Figure Lengend Snippet: (A) IHC assay indicated FGF23 expression in different uterine sarcoma subtypes. (B) The box plot and scatter plot shows the differential expression of FGF23 in AS, ESS, LMS, and UCS. FGF23 intensity: 1+ = weak, 2+ = moderate, 3+ = strong, FGF23 expression: 1+ = 1-25%, 2+ = 25-50%, 3+ = 50-75%, 4+ = ＞75%. IHC, immunohistochemistry; UCS, uterine carcinosarcoma; LMS, leiomyosarcoma; ESS, endometrial stromal sarcoma; AS, adenosarcoma.

    Article Snippet: Immunohistochemistry (IHC) was performed using a mouse anti­human FGF23 monoclonal antibody (NBP3-07378; Novus Biologicals, Colorado, USA).

    Techniques: Expressing, Immunohistochemistry

    (A) K-M analysis suggested overall survival of FGF23 high or low expression in 41 UCS patients from the TCGA cohort. (B) K-M analysis revealed the overall survival by FGF23 high or low expression in 50 UUS patients from the GEO database. (C) K-M analysis indicated no significant correlation between FGF23 expression levels and OS or PFS of US patients from the Suining cohort. (D) K-M analysis showed the differential OS and PFS between LG-ESS and other types of US patients from the Suining cohort. US, uterine sarcoma; TCGA, The Cancer Genome Atlas; FGF23, fibroblast growth factor 23; GEO, Gene Expression Omnibus; UCS, uterine carcinosarcoma; OS, overall survival; PFS, progression-free survival; LG-ESS, low-grade endometrial stromal sarcoma; UUS, undifferentiated uterine sarcoma.

    Journal: Technology in Cancer Research & Treatment

    Article Title: Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma

    doi: 10.1177/15330338241245924

    Figure Lengend Snippet: (A) K-M analysis suggested overall survival of FGF23 high or low expression in 41 UCS patients from the TCGA cohort. (B) K-M analysis revealed the overall survival by FGF23 high or low expression in 50 UUS patients from the GEO database. (C) K-M analysis indicated no significant correlation between FGF23 expression levels and OS or PFS of US patients from the Suining cohort. (D) K-M analysis showed the differential OS and PFS between LG-ESS and other types of US patients from the Suining cohort. US, uterine sarcoma; TCGA, The Cancer Genome Atlas; FGF23, fibroblast growth factor 23; GEO, Gene Expression Omnibus; UCS, uterine carcinosarcoma; OS, overall survival; PFS, progression-free survival; LG-ESS, low-grade endometrial stromal sarcoma; UUS, undifferentiated uterine sarcoma.

    Article Snippet: Immunohistochemistry (IHC) was performed using a mouse anti­human FGF23 monoclonal antibody (NBP3-07378; Novus Biologicals, Colorado, USA).

    Techniques: Expressing

    Sesn2 knockout aggravates obesity in female mice. ( A - B ) mice in four groups; ( C ) body weight; ( D - E ) fat mass; ( F ) FFA; ( G ) TG; ( H ) FBG; ( I - J ) OGTT and ITT; n = 4–6/group. * P < 0.05; # P < 0.05 vs. KO-NC. + P < 0.05 vs. WT-HFD

    Journal: Nutrition & Metabolism

    Article Title: Sestrin2 knockout exacerbates high-fat diet induced metabolic disorders and complications in female mice

    doi: 10.1186/s12986-024-00834-8

    Figure Lengend Snippet: Sesn2 knockout aggravates obesity in female mice. ( A - B ) mice in four groups; ( C ) body weight; ( D - E ) fat mass; ( F ) FFA; ( G ) TG; ( H ) FBG; ( I - J ) OGTT and ITT; n = 4–6/group. * P < 0.05; # P < 0.05 vs. KO-NC. + P < 0.05 vs. WT-HFD

    Article Snippet: Six-week-old female C57BL/6J mice (Pengyue Animal Breeding Co., Ltd.) and Sesn2 whole-body KO mice (Cyagen Biosciences Inc.) accommodated in ventilated cages.

    Techniques: Knock-Out

    Sesn2 knockout aggravates liver injury in female mice ( A ) ALT; ( B ) AST; ( C ) Ccl2 mRNA levels ( D ) Il6 mRNA levels; ( E - G ) H&E, Masson’s staining and Oil O Red; ( H - J ) Western blot for AMPK and mTOR; n = 4–5/group, * P < 0.05

    Journal: Nutrition & Metabolism

    Article Title: Sestrin2 knockout exacerbates high-fat diet induced metabolic disorders and complications in female mice

    doi: 10.1186/s12986-024-00834-8

    Figure Lengend Snippet: Sesn2 knockout aggravates liver injury in female mice ( A ) ALT; ( B ) AST; ( C ) Ccl2 mRNA levels ( D ) Il6 mRNA levels; ( E - G ) H&E, Masson’s staining and Oil O Red; ( H - J ) Western blot for AMPK and mTOR; n = 4–5/group, * P < 0.05

    Article Snippet: Six-week-old female C57BL/6J mice (Pengyue Animal Breeding Co., Ltd.) and Sesn2 whole-body KO mice (Cyagen Biosciences Inc.) accommodated in ventilated cages.

    Techniques: Knock-Out, Staining, Western Blot

    Sesn2 knockout aggravates cardiac dysfunction in female Mice. ( A - B ) cardiac dysfunction (E/F ratio and E/A ratio); ( C - E ) H&E and Masson’s staining; n = 4–5/group, * P < 0.05

    Journal: Nutrition & Metabolism

    Article Title: Sestrin2 knockout exacerbates high-fat diet induced metabolic disorders and complications in female mice

    doi: 10.1186/s12986-024-00834-8

    Figure Lengend Snippet: Sesn2 knockout aggravates cardiac dysfunction in female Mice. ( A - B ) cardiac dysfunction (E/F ratio and E/A ratio); ( C - E ) H&E and Masson’s staining; n = 4–5/group, * P < 0.05

    Article Snippet: Six-week-old female C57BL/6J mice (Pengyue Animal Breeding Co., Ltd.) and Sesn2 whole-body KO mice (Cyagen Biosciences Inc.) accommodated in ventilated cages.

    Techniques: Knock-Out, Staining

    Sesn2 knockout aggravates renal injury in female mice ( A ) 24-hour UAE; ( B ) 24-hour urinary volume; ( C , D ) H&E and Masson’s staining; n = 5/group * P < 0.05

    Journal: Nutrition & Metabolism

    Article Title: Sestrin2 knockout exacerbates high-fat diet induced metabolic disorders and complications in female mice

    doi: 10.1186/s12986-024-00834-8

    Figure Lengend Snippet: Sesn2 knockout aggravates renal injury in female mice ( A ) 24-hour UAE; ( B ) 24-hour urinary volume; ( C , D ) H&E and Masson’s staining; n = 5/group * P < 0.05

    Article Snippet: Six-week-old female C57BL/6J mice (Pengyue Animal Breeding Co., Ltd.) and Sesn2 whole-body KO mice (Cyagen Biosciences Inc.) accommodated in ventilated cages.

    Techniques: Knock-Out, Staining

    Sesn2 knockout aggravates adipose dysfunction in female mice ( A - B ) Atgl and Lpl in inguinal WAT; ( C - D ) Cidea and Ucp1 in BAT; ( E - F ) Adrb3 and Ucp1 in inguinal WAT; ( G - K ) Pgc1α , Sirt1 , Adipoq , Il6 and Tnf in inguinal WAT; ( L ) UCP-1 protein in BAT. n = 4–6, * P < 0.05

    Journal: Nutrition & Metabolism

    Article Title: Sestrin2 knockout exacerbates high-fat diet induced metabolic disorders and complications in female mice

    doi: 10.1186/s12986-024-00834-8

    Figure Lengend Snippet: Sesn2 knockout aggravates adipose dysfunction in female mice ( A - B ) Atgl and Lpl in inguinal WAT; ( C - D ) Cidea and Ucp1 in BAT; ( E - F ) Adrb3 and Ucp1 in inguinal WAT; ( G - K ) Pgc1α , Sirt1 , Adipoq , Il6 and Tnf in inguinal WAT; ( L ) UCP-1 protein in BAT. n = 4–6, * P < 0.05

    Article Snippet: Six-week-old female C57BL/6J mice (Pengyue Animal Breeding Co., Ltd.) and Sesn2 whole-body KO mice (Cyagen Biosciences Inc.) accommodated in ventilated cages.

    Techniques: Knock-Out

    Sesn2 knockout exacerbates high-fat diet induced metabolic disorders and complications in female mice

    Journal: Nutrition & Metabolism

    Article Title: Sestrin2 knockout exacerbates high-fat diet induced metabolic disorders and complications in female mice

    doi: 10.1186/s12986-024-00834-8

    Figure Lengend Snippet: Sesn2 knockout exacerbates high-fat diet induced metabolic disorders and complications in female mice

    Article Snippet: Six-week-old female C57BL/6J mice (Pengyue Animal Breeding Co., Ltd.) and Sesn2 whole-body KO mice (Cyagen Biosciences Inc.) accommodated in ventilated cages.

    Techniques: Knock-Out

    (A) IHC indicated the expression levels of FGF23 in the UNSM, ULM and US groups. (B) The box plot shows FGF23 expression in US, ULM, and UNSM among 6 paired samples. (C) The box plot shows FGF23 expression in US and UNSM among 32 paired samples.

    Journal: medRxiv

    Article Title: FGF23 is a potential prognostic biomarker in uterine sarcoma

    doi: 10.1101/2023.08.20.23294198

    Figure Lengend Snippet: (A) IHC indicated the expression levels of FGF23 in the UNSM, ULM and US groups. (B) The box plot shows FGF23 expression in US, ULM, and UNSM among 6 paired samples. (C) The box plot shows FGF23 expression in US and UNSM among 32 paired samples.

    Article Snippet: Immunohistochemistry was performed using a mouse anti-human FGF23 monoclonal antibody (NBP3-07378; Novus Biologicals, Colorado, USA).

    Techniques: Expressing

    (A) IHC assay indicated FGF23 expression in different uterine sarcoma subtypes. (B) The box plot shows the differential expression of FGF23 in AS, ESS, LMS and UCS.

    Journal: medRxiv

    Article Title: FGF23 is a potential prognostic biomarker in uterine sarcoma

    doi: 10.1101/2023.08.20.23294198

    Figure Lengend Snippet: (A) IHC assay indicated FGF23 expression in different uterine sarcoma subtypes. (B) The box plot shows the differential expression of FGF23 in AS, ESS, LMS and UCS.

    Article Snippet: Immunohistochemistry was performed using a mouse anti-human FGF23 monoclonal antibody (NBP3-07378; Novus Biologicals, Colorado, USA).

    Techniques: Expressing

    (A) K-M analysis suggested overall survival of FGF23 high or low expression in 41 UCS patients from the TCGA cohort. (B) K-M analysis revealed the overall survival by FGF23 high or low expression in 50 UUS patients from the GEO database. (C) K-M analysis indicated no significant correlation between FGF23 expression levels and OS or PFS of US patients from the clinical cohort. (D) K-M analysis showed the differential OS and PFS between LG-ESS and other types of US patients from the clinical cohort.

    Journal: medRxiv

    Article Title: FGF23 is a potential prognostic biomarker in uterine sarcoma

    doi: 10.1101/2023.08.20.23294198

    Figure Lengend Snippet: (A) K-M analysis suggested overall survival of FGF23 high or low expression in 41 UCS patients from the TCGA cohort. (B) K-M analysis revealed the overall survival by FGF23 high or low expression in 50 UUS patients from the GEO database. (C) K-M analysis indicated no significant correlation between FGF23 expression levels and OS or PFS of US patients from the clinical cohort. (D) K-M analysis showed the differential OS and PFS between LG-ESS and other types of US patients from the clinical cohort.

    Article Snippet: Immunohistochemistry was performed using a mouse anti-human FGF23 monoclonal antibody (NBP3-07378; Novus Biologicals, Colorado, USA).

    Techniques: Expressing